Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology.
about
The linker region in receptor guanylyl cyclases is a key regulatory module: mutational analysis of guanylyl cyclase CGuanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral painSolution structure of human proguanylin: the role of a hormone prosequenceInteraction of guanylyl cyclase C with SH3 domain of Src tyrosine kinase. Yet another mechanism for desensitizationRenal effects of serine-7 analog of lymphoguanylin in ex vivo rat kidney.Gene expression profiling of colorectal tumors and normal mucosa by microarrays meta-analysis using prediction analysis of microarray, artificial neural network, classification, and regression trees.Porphyrins, porphyrin metabolism and porphyrias. I. Update.Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.Natriuretic and antikaliuretic effects of uroguanylin and prouroguanylin in the ratPlecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC miceBacterial enterotoxins are associated with resistance to colon cancer.Diarrhea or colorectal cancer: can bacterial toxins serve as a treatment for colon cancer?Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics.Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells.Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic PerspectivePharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis.Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cellsRecent developments in the therapy of irritable bowel syndrome.Development of drugs for gastrointestinal motor disorders: translating science to clinical need.Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Current and novel therapeutic options for irritable bowel syndrome management.GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?Can colorectal cancer be prevented or treated by oral hormone replacement therapy?Temporal and spatial regulation of cAMP signaling in disease: role of cyclic nucleotide phosphodiesterases.American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.Products for the treatment of inflammatory bowel disease: a patent review (2013 - 2014).Defying the stereotype: non-canonical roles of the Peptide hormones guanylin and uroguanylin.Release of endogenous opioids from duodenal enteroendocrine cells requires Trpm5Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy.Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog.Melatonin-induced calcium signaling in clusters of human and rat duodenal enterocytes.Taking a lesson from microbial diarrheagenesis in the management of chronic constipation.Guanylin and its lysine-containing analogue in the isolated perfused rat kidney: interaction with chymotrypsin inhibitor.Guanylin peptides regulate electrolyte and fluid transport in the Gulf toadfish (Opsanus beta) posterior intestine.Duodenal bicarbonate secretion in rats: stimulation by intra-arterial and luminal guanylin and uroguanylin.Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.Polar Effects on Ion Transport and Cell Proliferation Induced by GC-C Ligands in Intestinal Epithelial Cells.
P2860
Q24647874-1979A527-3A6D-442E-B61F-CE70BE57C118Q26863234-B14FC291-3348-431B-AF1F-73845287BF21Q27641038-5D2F7CFA-98E0-4F92-BCED-15F84A2A62BDQ28185390-7F05A3AE-DFBA-4E0E-94C1-E05D54E571F8Q32031997-5FA9D3E4-16C8-4E5C-8319-57203E4549AFQ33747019-D5F28A8E-847E-495E-88C3-B02F2FA896C2Q33934680-E69B9E7B-828D-42F9-B7E0-9EB8737146BBQ34409219-FEF491D6-B404-4F85-B698-468F44BAC891Q34426358-9ACA8C35-7AAD-4AB6-9B3B-ADA90C13D1A3Q34551599-15B050C4-2F18-4003-9A9F-E533E60A0243Q34808083-36EC4B0D-38D7-481C-95DD-0FFE5A4372C5Q34865462-D0B3D752-785A-4A83-9C42-22E8810EDD49Q35155933-48758DD5-7246-453A-8AE2-03B6EEE0B416Q36526265-3035293C-94BB-451E-8BF7-F674DF598638Q36604130-AC3F13BA-21EF-4A71-9170-854BC44C68FDQ36790193-A2391405-D265-40D0-A9B6-DE2BDC83F3F7Q36838038-0EF092A3-1D4C-4BF2-8D89-9AD6C56ACD71Q37071175-4F20EBF7-0BEE-4CA0-BD64-098E8795CF22Q37079261-DC6B71E0-1B76-468E-BE60-076791DD8487Q37164063-75BE2121-C89F-4866-A035-732BEA9D7484Q37438547-45D90BF6-0784-4C4C-98A3-96CF9C21CABAQ37601318-CAFBED20-2C6E-4B56-9A3A-65B2E890692AQ37659196-009758C4-DB66-4E43-846B-8E01572671F2Q38205932-1F1EAEFD-2935-4A03-9877-C4C26F296BB3Q38236812-0853D670-3D13-4486-A382-CE4F063873BFQ38445280-C907C1C9-921C-4855-9807-30B5DEF17B2BQ38461139-3482F484-53E4-4265-AED8-E69C5208DA41Q41895539-791448E1-F485-422B-887B-F8D11A1E5518Q42044354-DEC6F213-42B7-4E43-8C07-AF11DEDCC6D5Q42277641-8DFC051B-8B92-4C9C-8DE8-625CC4E3BC66Q42293861-9DFCAFC7-83D8-47BF-A084-76414467E308Q42437023-2C923487-AECF-454A-9961-D13BD5B8991AQ42836463-F3291C77-D020-4EBC-B0FF-795889B4398BQ44445224-E6DE6A6F-A4F1-4E96-A10D-493405AC0A2AQ45001876-9450A91D-F789-48E5-899F-C94389D39567Q46905852-2923EDA6-952C-4019-A93A-6E273F03BFB6Q48349012-E4994096-5D89-4890-B700-7032A63DD047Q54378105-CE028B01-EE97-4274-ABBB-361F5FF8805A
P2860
Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Guanylin regulatory peptides: ...... y cyclic GMP and pathobiology.
@ast
Guanylin regulatory peptides: ...... y cyclic GMP and pathobiology.
@en
type
label
Guanylin regulatory peptides: ...... y cyclic GMP and pathobiology.
@ast
Guanylin regulatory peptides: ...... y cyclic GMP and pathobiology.
@en
prefLabel
Guanylin regulatory peptides: ...... y cyclic GMP and pathobiology.
@ast
Guanylin regulatory peptides: ...... y cyclic GMP and pathobiology.
@en
P1433
P1476
Guanylin regulatory peptides: ...... y cyclic GMP and pathobiology.
@en
P2093
P356
10.1016/S0167-0115(99)00033-6
P577
1999-05-01T00:00:00Z